

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Acerus Pharmaceuticals Corporation, *et al.*,

Debtors in a foreign proceeding.¹

Chapter 15

Case No. 23-10111 (MFW)

(Jointly Administered)

Re: D.I. 50, 54

**NOTICE OF HEARING ON FOREIGN REPRESENTATIVE’S MOTION FOR ENTRY
OF AN ORDER (I) RECOGNIZING AND ENFORCING THE CCAA SISP APPROVAL
ORDER AND (II) GRANTING RELATED RELIEF**

PLEASE TAKE NOTICE that on March 14, 2023, Acerus Pharmaceuticals Corporation, as the duly authorized foreign representative (the “**Foreign Representative**”) of the above-captioned debtors (collectively, the “**Debtors**”), filed the *Foreign Representative’s Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA SISP Approval Order and (II) Granting Related Relief* [D.I. 50] (the “**Motion**”),² with the United States Bankruptcy Court for the District of Delaware (the “**Court**”).

PLEASE TAKE FURTHER NOTICE that, pursuant to the *Order Pursuant to Bankruptcy Rule 9006(c) and Local Rule 9006-1(e) Shortening the Notice Period for Foreign Representative’s Motion for Entry of an Order (I) Recognizing and Enforcing the CCAA SISP Approval Order and (II) Granting Related Relief* [D.I. 54] (the “**Order Shortening Notice**”), a hearing on the Motion will take place on **Thursday, March 23, 2023, at 3:00 p.m. (prevailing Eastern Time)**, before the Honorable Mary F. Walrath, United States Bankruptcy Judge, at the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801.

PLEASE TAKE FURTHER NOTICE that, pursuant to the Order Shortening Notice, objections or responses to the relief requested in the Motion shall be filed no later than **4:00 p.m. (prevailing Eastern Time) on March 21, 2023**.

PLEASE TAKE FURTHER NOTICE that copies of the documents referenced above may be obtained free of charge on the site maintained by Ernst & Young Inc., the court-appointed Monitor in the Canadian Proceedings: <https://www.ey.com/ca/acerus>. You may also obtain copies from the Court’s website at www.deb.uscourts.gov for a fee.

¹ The Debtors in these chapter 15 proceedings, together with the last four digits of their business identification numbers are: Acerus Pharmaceuticals Corporation (6891); Acerus Biopharma Inc. (0687); Acerus Labs Inc. (0126); and Acerus Pharmaceuticals USA, LLC (9089). The location of the Debtors’ headquarters and the Debtors’ foreign representative is: 205-7025 Langer Drive, Mississauga, Ontario, Canada.

² Capitalized terms used but not defined herein have the meanings ascribed to them in the Motion.

PLEASE TAKE FURTHER NOTICE THAT IF NO RESPONSES OR OBJECTIONS ARE RECEIVED IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RELIEF REQUESTED IN THE MOTION WITHOUT FURTHER NOTICE OR HEARING.

Dated: March 15, 2023
Wilmington, Delaware

Respectfully submitted,

**BENESCH, FRIEDLANDER, COPLAN
& ARONOFF LLP**

/s/ Jennifer R. Hoover

Michael J. Barrie (DE No. 4684)
Jennifer R. Hoover (DE No. 5111)
Steven L. Walsh (DE No. 6499)
1313 North Market Street, Suite 1201
Wilmington, DE 19801
Telephone: (302) 442-7010
Facsimile: (302) 442-7012
E-mail: mbarrie@beneschlaw.com
jhoover@beneschlaw.com
swalsh@beneschlaw.com

-and-

SIDLEY AUSTIN LLP

William E. Curtin (admitted *pro hac vice*)
Michael A. Sabino (admitted *pro hac vice*)
787 Seventh Avenue
New York, New York 10019
Telephone: (212) 839-5300
Facsimile: (212) 839-5599
Email: wcurtin@sidley.com
msabino@sidley.com

Counsel to the Foreign Representative